![]() ![]() Miller TW, Rexer BN, Garrett JT, Arteaga CL. Our data indicates that DDR1 inhibition can augment cell cycle suppressive effect of palbociclib and could be effective strategy for targeted therapy of ER-positive, HER2-negative breast cancers with PI3K pathway activation. In vivo, 7rh significantly enhanced palbociclib’s antitumor efficacy. Combined treatment of palbociclib and 7rh further induced cell cycle arrest in PIK3CA/ AKT1 mutant cell lines. DDR1 knockdown and DDR1 pharmacological inhibitor decreased cell growth and inhibited cell cycle progression in all cell lines, while enhanced the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib. We also identified that the downregulation of discoidin domain receptor 1 ( DDR1) is synthetically lethal with palbociclib. ![]() We demonstrated that the efficacy of palbociclib is reduced in the presence of PIK3CA/ AKT1 mutations. We utilized a barcoded shRNA library to determine critical targets for survival in isogenic MCF7 cells with PIK3CA/ AKT1 mutations. The purpose of this study was identifying synthetic lethality partners that can enhance palbociclib’s antitumor efficacy in the presence of PIK3CA/ AKT1 mutations. Although this is an effective regimen, most patients ultimately progress. Patients with ER-positive, HER2-negative metastatic breast cancer are often treated with CDK4/6 inhibitors such as palbociclib in combination with endocrine therapy. Molecular alterations in the PI3K/AKT pathway occur frequently in hormone receptor-positive breast tumors. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |